Site Feedback

Website Feedback

This contact form is only for website help or website suggestions. If you have questions or comments regarding a published document please contact the publishing agency. Comments or questions about document content can not be answered by OFR staff. Please do not provide confidential information or personal data.

Title 21

Displaying title 21, up to date as of 7/20/2026. Title 21 was last amended 7/20/2026.
view historical versions
  1. Title 21 —Food and Drugs
  2. Chapter I —Food and Drug Administration, Department of Health and Human Services
  3. Subchapter D —Drugs for Human Use
  4. Part 314 —Applications for FDA Approval to Market a New Drug
  5. Subpart D   View Full Text
  • Details
  • Print
  • Search
  • Subscribe
  • Timeline
  • Go to Date
  • Published Edition
  • Developer Tools
eCFR Content

The Code of Federal Regulations (CFR) is the official legal print publication containing the codification of the general and permanent rules published in the Federal Register by the departments and agencies of the Federal Government. The Electronic Code of Federal Regulations (eCFR) is a continuously updated online version of the CFR. It is not an official legal edition of the CFR.

Learn more about the eCFR, its status, and the editorial process.

Title 21Food and DrugsPart / Section
Chapter IFood and Drug Administration, Department of Health and Human Services1 – 1299
Subchapter DDrugs for Human Use300 – 499
Part 314Applications for FDA Approval to Market a New Drug314.1 – 314.650
Subpart DFDA Action on Applications and Abbreviated Applications314.100 – 314.170
§ 314.100Timeframes for reviewing applications and abbreviated applications.
§ 314.101Filing an NDA and receiving an ANDA.
§ 314.102Communications between FDA and applicants.
§ 314.103Dispute resolution.
§ 314.104Drugs with potential for abuse.
§ 314.105Approval of an NDA and an ANDA.
§ 314.106Foreign data.
§ 314.107Date of approval of a 505(b)(2) application or ANDA.
§ 314.108New drug product exclusivity.
§ 314.110Complete response letter to the applicant.
§ 314.120 [Reserved]
§ 314.122Submitting an abbreviated application for, or a 505(j)(2)(C) petition that relies on, a listed drug that is no longer marketed.
§ 314.125Refusal to approve an NDA.
§ 314.126Adequate and well-controlled studies.
§ 314.127Refusal to approve an ANDA.
§ 314.150Withdrawal of approval of an application or abbreviated application.
§ 314.151Withdrawal of approval of an abbreviated new drug application under section 505(j)(5) of the act.
§ 314.152Notice of withdrawal of approval of an application or abbreviated application for a new drug.
§ 314.153Suspension of approval of an abbreviated new drug application.
§ 314.160Approval of an application or abbreviated application for which approval was previously refused, suspended, or withdrawn.
§ 314.161Determination of reasons for voluntary withdrawal of a listed drug.
§ 314.162Removal of a drug product from the list.
§ 314.170Adulteration and misbranding of an approved drug.
eCFR Content